15 assets in Vulvar Squamous Cell Carcinoma

Therapeutic assets addressing Vulvar Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Vulvar Squamous Cell Carcinoma	Christian Hinrichs	P2	B (58)
e7 tcr-t cells Vulvar Squamous Cell Carcinoma	Christian Hinrichs	P2	B (58)
Fludarabine Vulvar Squamous Cell Carcinoma	Christian Hinrichs	P2	B (58)
Atezolizumab Vulvar Squamous Cell Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Vulvar Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Vulvar Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
scg142 Vulvar Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CC (45)
Evolve104 Vulvar Squamous Cell Carcinoma	EvolveImmune United, Inc	P1	CC (43)
Tsc-200-A0201 Vulvar Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-201-B0702 Vulvar Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-202-A0201 Vulvar Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-203-A0201 Vulvar Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0101 Vulvar Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0201 Vulvar Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-C0702 Vulvar Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)